Seeking Alpha

Franklin D

Franklin D
Send Message
View as an RSS Feed
View Franklin D's Comments BY TICKER:
Latest  |  Highest rated
  • A High Risk-High Reward Biopharma With Two Pending Catalysts [View article]
    As a leading pharmacologist I like the idea of developing a selective N-type calcium channel blocker as an effective pain medication so I'm right behind $ZLCS all the way even if it sinks initially. Creamed off killings from former sinkers $DCTH $IDRA $DARA $GTXI recent burst to put free overnight money into this stock so no risk for me. I'll just watch it go back to 100 again !
    Oct 5, 2013. 12:58 AM | 2 Likes Like |Link to Comment
  • BioCryst Pharmaceuticals' Management Presents at 2013 Morgan Stanley Global Healthcare Conference (Transcript) [View article]
    BCRX could go much higher I'm buying in at 6.1
    Sep 16, 2013. 08:11 AM | Likes Like |Link to Comment
  • Take Your Profits On BioCryst Pharmaceuticals Stock [View article]
    $BCRX has a lot more growth left in it and could soon hit $ 9. Already last week it reached $ 7. Anyone selling too soon will be missing out on long term growth.
    Sep 3, 2013. 01:29 AM | 1 Like Like |Link to Comment
  • Terminal Diagnosis: Despite What You May Have Heard, Dendreon Is A 'Dead Company Walking' [View article]
    The problem with Dendreon is it only has a single product provenge that does not work. If it worked there would be some clinical evidence by now which there is not. It only survived when there was no competition for pre chemotherapy prostate cancer. Now that Zytiga and soon Xtandi are approved for this indication there is no longer demand for an expensive and still unproven treatment.
    Aug 25, 2013. 11:47 PM | Likes Like |Link to Comment
  • Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? [View article]
    I bought Array (ARRY) a few months back at around $ 4 and won't be selling these under $ 40 so definately a good long term investment. This company has more potential than Medivation (MDVN) which is currently at $ 50.
    May 13, 2013. 06:55 AM | Likes Like |Link to Comment
  • Here's My Argument Against Zytiga, Clinically Speaking [View instapost]
    I heard from someone who was in the Phase II trial of Abiraterone and has been on Zytiga for 5 years and has not suffered from any of the side effects mentioned in this article and is still responding to this drug.
    Dec 20, 2012. 04:59 AM | Likes Like |Link to Comment
  • Can Dendreon Stop The Medivation Invasion? [View article]
    Whats the point in sequencing in Provenge at all since it has not shown any clinical benefits. Xtandi poses a threat to Provenge because it will not be too long before Xtandi is prescribed off label in the pre chemotherapy setting where Provenge use is considered. Xtandi has shown much better clinical responses that Provenge so should be the preferred option.
    Oct 2, 2012. 03:45 PM | 2 Likes Like |Link to Comment
  • Exelixis' CEO Discusses Q2 2012 Results - Earnings Call Transcript [View article]
    Exelixis has an exciting new product in the shape of Cabozantinib which is showing promising results against bone mets in prostate cancer patients.
    Aug 3, 2012. 02:42 PM | Likes Like |Link to Comment
  • Dendreon: Who's That Knocking On Their Door? [View article]
    Provenge offers no discernable clinical benefits. Patients who have received Provenge report increasing PSA levels and increased spread of the cancer to the bones. No company in their right mind in the field of Oncology would touch Dendreon Corp who own the biggest white elephant in medical history.
    Jul 30, 2012. 04:06 PM | Likes Like |Link to Comment